Stock Research: Dr. Lal PathLabs

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Dr. Lal PathLabs

BSE:539524 INE600L01024
35
  • Value
    69
  • Growth
    67
  • Safety
    Safety
    15
  • Combined
    62
  • Sentiment
    25
  • 360° View
    360° View
    35
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The company offers a range of diagnostic services including core testing, patient diagnosis, prevention, monitoring, and treatment of various diseases, with tests such as Pregnancy Test, Full Body Checkups, Covid 19 Test, and more. It operates throughout India. In the last fiscal year, the company had a market cap of $2902 millions, profits of $229 millions, revenue of $288 millions, and 4980 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 35 (better than 35% compared with alternatives), overall professional sentiment and financial characteristics for the stock Dr. Lal PathLabs are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Dr. Lal PathLabs. The consolidated Growth Rank has a good rank of 67, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 67% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 69 which means that the company has a financing structure that is safer than 69% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 15 which means that the share price of Dr. Lal PathLabs is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 85% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 25, which means that professional investors are more pessimistic about the stock than for 75% of alternative investment opportunities. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
15 9 1 1
Growth
67 53 83 91
Safety
Safety
69 61 50 56
Sentiment
25 13 37 6
360° View
360° View
35 12 27 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
29 29 3 7
Opinions Change
50 28 50 32
Pro Holdings
n/a 53 77 56
Market Pulse
24 24 65 41
Sentiment
25 13 37 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
15 9 1 1
Growth
67 53 83 91
Safety Safety
69 61 50 56
Combined
62 22 42 46
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
20 17 7 1
Price vs. Earnings (P/E)
12 11 7 1
Price vs. Book (P/B)
11 10 10 1
Dividend Yield
40 42 26 23
Value
15 9 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
65 65 62 45
Profit Growth
35 52 75 70
Capital Growth
83 32 90 81
Stock Returns
59 65 33 91
Growth
67 53 83 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
69 56 50 72
Refinancing
35 31 27 27
Liquidity
65 63 53 59
Safety Safety
69 61 50 56

Similar Stocks

Discover high‑ranked alternatives to Dr. Lal PathLabs and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

NMDC

BSE:526371
Country: India
Industry: Steel
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.